Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Highlights d CD49f is a novel, reactivity-independent marker for human astrocytes d CD49f can be used to purify human fetal astrocytes and iPSCderived astrocytes d CD49f + hiPSC-astrocytes acquire an A1-like reactive state upon cytokine stimulation d CD49f + A1-like reactive astrocytes are dysfunctional and toxic to neurons in vitro